Covered, compounding. A 1.58% yield on a 53.47% payout is covered income on an essential-services base: $0.945 a quarter, raised 14.5% for 2026 from $0.825, marking the 23rd consecutive year of increases. The raise, announced with a new $3 billion buyback authorization, rests on contracted collection and disposal cash flow rather than a cyclical upswing.
Key risk: Leverage after Stericycle — leverage near 3.1× at the end of 2025, targeted back to 2.5–3.0× during 2026, leaves less room if recycling prices or healthcare-waste integration slip while the buyback resumes.
Changes if: Free cash flow falls toward the $3.78 indicated dividend, or leverage stalls above 3.0×. Either would put the raise pace, not just the current rate, at risk.
- ✓Payout-coverage check: 53.47% of trailing earnings — the $3.78 indicated dividend leaves roughly half of earnings retained, with free cash flow projected to rise toward $3.8 billion in 2026.
- ✓Yield check: 1.58% indicated — $0.945/qtr × 4 at the $239.38 close on Oct. 23, 2026. Real, earned yield for a single stock, not a special or a return of capital.
- ✓Dividend growth check: 23rd consecutive year of increases; the 2026 step lifted the quarterly dividend 14.5%, from $0.825 to $0.945.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.